Program
cabozantinib
Also written as “Cabozantinib”, “XL184” and “Cabozantinib tablets”.
Its studies are mostly in Neoplasms · Carcinoma, Renal Cell · Prostatic Neoplasms · Carcinoma, Hepatocellular · Glioblastoma, led by 5 companies.
Drug pageCabozantinib: every studyMany companies study it; this page follows only the 33 they lead. All 223 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Exelixisits history only | 237 open or running | phase 4since Jul 8, 2013 | Sep 20, 2005 | May 31, 2030phase 3 · NCT07620574 |
| Bristol-Myers Squibbits history only | 51 open or running | phase 3since May 3, 2017 | Nov 24, 2009 | Aug 25, 2029phase 2 · NCT03899155 |
| Ipsen | 20 open or running | phase 2since May 9, 2019 | May 9, 2019 | none ahead |
| Takedaits history only | 20 open or running | phase 2since Nov 8, 2017 | Nov 8, 2017 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Apr 23, 2018 | Apr 23, 2018 | none ahead |
Also a collaborator on its studies: Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Roche-Genentech and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Ipsen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 9, 2019First study: phase 2 study in Carcinoma, Renal CellFirst studyNCT03945773 · 127 enrolled · Austria, France, Germany and more
- Mar 4, 2024Phase 2 study in OsteosarcomaNCT06341712 · 10 enrolled · United States, Belgium, Canada and more
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zanzalintinibrule | Exelixis | phase 3 | 17 |
Studies
All 2 Ipsen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06341712Osteosarcoma · United States, Belgium, Canada and more | 2 | Terminated | Feb 27, 2026 | 10 |
| NCT03945773Carcinoma, Renal Cell · Austria, France, Germany and more | 2 | Completed | May 11, 2023 | 127 |
How it is read
Names in the registry
- “Cabozantinib”, 18 entries
- “cabozantinib”, 9 entries
- “XL184”, 6 entries
- “Cabozantinib tablets”, 2 entries
- “Cabozantinib (XL184) 140 mg”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 6 studies
- Carcinoma, Renal Cell, 5 studies
- Prostatic Neoplasms, 4 studies
- Carcinoma, Hepatocellular, 4 studies
- Glioblastoma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.